Insulin Or Derivative Utilizing Patents (Class 514/5.9)
-
Publication number: 20130165371Abstract: A spray-drying apparatus includes a drying chamber that has a first end, a second end, and at least one side wall extending between the first and second ends to define an interior of the drying chamber having a center axis. A nozzle can be positioned at the first end of the drying chamber and be configured to atomize liquid and spray the atomized liquid into the interior of the drying chamber at a maximum spray pattern angle relative to the center axis. A heating device can be provided to heat the liquid prior to introduction into the drying chamber.Type: ApplicationFiled: September 1, 2011Publication date: June 27, 2013Applicant: BEND RESEARCH, INC.Inventors: Daniel E. Dobry, James M. Mullin, Douglas L. Millard, Dwayne T. Friesen, David D. Newbold, John M. Baumann, Devon B. Dubose
-
Publication number: 20130156817Abstract: A container containing a therapeutic protein, characterized in that chaperones molecules are bound by a molecular linker to an inner surface of the container. The linker being interposed between the surface and the chaperone.Type: ApplicationFiled: March 5, 2010Publication date: June 20, 2013Applicant: BECTON DICKINSON FRANCEInventors: Thomas Ballet, Paolo Mangiagalli
-
Publication number: 20130157938Abstract: The present invention is related to insulin derivatives containing additional disulfide bonds and methods of making such.Type: ApplicationFiled: June 21, 2011Publication date: June 20, 2013Applicant: NOVO NORDISK A/SInventors: Peter Madsen, Frantisek Hubalek, Thomas Boerglum Kjeldsen, Svend Ludvigsen
-
Publication number: 20130157939Abstract: The present invention relates to compositions, including pharmaceutical compositions for oral administration, comprising: at least one therapeutically active agent; at least one surface active agent; at least one ester of poly-carboxylic acid and/or at least one ester of an aromatic carboxylic acid; and a non-aqueous medium, for use in the gastric absorption of said at least one therapeutically active agent of the composition and methods of oral administration of at least one therapeutically active agent utilizing compositions of the invention.Type: ApplicationFiled: August 18, 2011Publication date: June 20, 2013Inventor: Shmuel Ben-Sasson
-
Publication number: 20130150291Abstract: The present invention relates in part to agents which provide slow absorption from an injection site. In some embodiments, the pharmaceutical compositions comprises an insulin amino acid sequence and an amino acid sequence that provide slow absorption from an injection site, such as, for example, an amino acid sequence that has a substantially repeating pattern of proline residues.Type: ApplicationFiled: November 28, 2012Publication date: June 13, 2013Applicant: PHASEBIO PHARMACEUTICALS, INC.Inventor: PhaseBio Pharmaceuticals, Inc.
-
Publication number: 20130143801Abstract: Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration. The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biological membrane in order to facilitate transport. In one embodiment, insulin is administered via the pulmonary delivery of microparticles comprising fumaryl diketopiperazine and insulin in its biologically active form. This method of delivering insulin results in a rapid increase in blood insulin concentration that is comparable to the increase resulting from intravenous delivery.Type: ApplicationFiled: January 30, 2013Publication date: June 6, 2013Inventors: Solomon S. Steiner, Rodney J. Woods, Joseph W. Sulner
-
Publication number: 20130143800Abstract: Provided are methods for treating diabetes comprising administering to a patient a GLP-1 agonist and an iron chelator. In various embodiments, methods are provided for culturing pancreatic beta islet cells comprising contacting the beta cells with a GLP-1 agonist and an iron chelator in an amount effective to promote survival of the beta cells.Type: ApplicationFiled: November 7, 2012Publication date: June 6, 2013Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventor: Research Development Foundation
-
Patent number: 8450097Abstract: The application relates to a composition comprising a hyperbranched polymer attached to a core and a biologically active moiety. The biologically active moiety is attached to the core by means of a substantially non-enzymatically cleavable linker L. The composition can be used to deliver the biologically active moiety to its target.Type: GrantFiled: December 14, 2010Date of Patent: May 28, 2013Assignee: Ascendis Pharma GmbHInventors: Dirk Vetter, Ulrich Hersel, Harald Rau, Robert Schnepf, Thomas Wegge
-
Publication number: 20130130973Abstract: The present invention relates to PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit improved pharmacokinetic and biological activity in vivo.Type: ApplicationFiled: November 19, 2012Publication date: May 23, 2013Applicant: CEBIX ABInventor: CEBIX AB
-
Patent number: 8440614Abstract: This invention is an improved process to formulate polymeric microspheres/nanospheres and encapsulate therapeutic proteins or other useful substances, and a polymer sphere apparatus. The invention is also methods of purifying protein-containing-polymeric-microspheres from unused polymer, and an apparatus therefore.Type: GrantFiled: December 2, 2011Date of Patent: May 14, 2013Assignee: Aphios CorporationInventor: Trevor P. Castor
-
Publication number: 20130116175Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: ApplicationFiled: December 31, 2012Publication date: May 9, 2013Applicant: Yeda Research and Development Co., Ltd.Inventors: Yoram SHECHTER, Matityahu Fridkin, Haim Tsubery
-
Patent number: 8435942Abstract: A method of formulating insulin compositions comprises preparing a carrier having a phosphatidylcholine component which entraps insulin, stabilizing insulin compositions at room temperatures.Type: GrantFiled: December 31, 2003Date of Patent: May 7, 2013Assignee: Transdermal Biotechnology, Inc.Inventors: Nicholas V. Perricone, Chim Potini
-
Patent number: 8431161Abstract: A microparticle includes an agglomerate of a hydrophilic active substance containing particle, which particle includes an amphiphilic polymer composed of a hydrophobic segment of poly(hydroxy acid) and a hydrophilic segment of polysaccharides or polyethylene glycol, and a hydrophilic active substance. It is characterized by an efficient inclusion of the hydrophilic active substance, and a release of the hydrophilic active substance at an appropriate speed in the human body, and is hence very useful as a DDS pharmaceutical preparation.Type: GrantFiled: February 20, 2009Date of Patent: April 30, 2013Assignee: Toray Industries, Inc.Inventors: Yoshinori Kakizawa, Reiji Nishio, Junji Michizoe, Masakazu Koiwa, Nobuo Ida, Taisuke Hirano, Yoichiro Koshi
-
Patent number: 8426362Abstract: A supramolecular insulin assembly and supramolecular exendin-4 assembly, which is useful as a protein therapeutic agent for the treatment of metabolic disorders particularly diabetes. The supramolecular assemblies disclosed in the present invention consists of insoluble and aggregated oligomers the protein. The invention also provides pharmaceutical compositions comprising the supramolecular assembly.Type: GrantFiled: April 7, 2009Date of Patent: April 23, 2013Assignees: National Institute of Immunology, Indian Institute of ScienceInventors: Avadhesha Surolia, Sarika Gupta, Mahendra Pal Singh, Tandrika Chattopadhyay
-
Publication number: 20130096056Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where V, W, R1, R2, R3 and R4 are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.Type: ApplicationFiled: September 14, 2012Publication date: April 18, 2013Applicant: XENON PHARMACEUTICALS INC.Inventors: Jianmin Fu, Duanjie Hou, Rajender Kamboj, Vishnumurthy Kodumuru, Natalia Pokrovskaia, Vandna Raina, Shaoyi Sun, Serguei Sviridov, Zaihui Zhang
-
Patent number: 8420092Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.Type: GrantFiled: March 18, 2010Date of Patent: April 16, 2013Assignees: Ben-Gurion University of the Negev Research and Development Authority, Hadasit Medical Research Services and Development Ltd.Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
-
Publication number: 20130090288Abstract: The present invention relates to pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes. Said pharmaceutical compositions contain said at least one protein active ingredient, in free form, as well as, for liquids, a system that buffers them to a pH greater than 4 and less than or equal to 8 or, for solids, a system that exerts, when they are placed a liquid medium, a buffer effect between a pH greater than 4 and a pH less than or equal to 8.Type: ApplicationFiled: November 12, 2012Publication date: April 11, 2013Inventors: Farid Bennis, Jean-Jacques Serrano
-
Publication number: 20130085099Abstract: The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistence in the body, solubility, and bioavailability.Type: ApplicationFiled: June 15, 2012Publication date: April 4, 2013Applicant: DUKE UNIVERSITYInventor: Ashutosh Chilkoti
-
Patent number: 8410049Abstract: Improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.Type: GrantFiled: March 4, 2010Date of Patent: April 2, 2013Assignee: CebixInventors: John Wahren, Karin Ekberg, James Callaway
-
Patent number: 8410048Abstract: The invention relates to a method for producing a type of insulin by genetically engineering a precursor thereof and converting said precursor to the respective insulin in an enzyme-catalyzed ligation reaction with lysine amide or arginine amide, or by lysine or arginine which is modified by protective groups, and optionally subsequent hydrolysis.Type: GrantFiled: January 7, 2009Date of Patent: April 2, 2013Assignee: Sanofi-Aventis Deutschland GmbHInventors: Paul Habermann, Frank Zocher
-
Patent number: 8399407Abstract: An insulin analogue comprises a B-chain polypeptide containing at least one alteration selected from a methylated phenylalanine substitution at position B24 and an addition of two amino acids to the carboxyl end of the B-chain polypeptide. A first amino acid at position B31 is selected from glutamate and aspartate, and a second amino acid at position B32 is selected from glutamate, alanine and aspartate. The methylated phenylalanine may be ortho-monofluoro-phenylalanine, meta-monobromo-phenylalanine or para-monochloro-phenylalanine. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.Type: GrantFiled: September 17, 2010Date of Patent: March 19, 2013Assignee: Case Western Reserve UniversityInventor: Michael A. Weiss
-
Publication number: 20130065826Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a pH of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.Type: ApplicationFiled: August 9, 2012Publication date: March 14, 2013Applicant: ADOCIAInventors: Olivier SOULA, Gérard SOULA, Jeff TONNAR
-
Patent number: 8394766Abstract: Diabetic and other patients are treated using an aggressive form of Pulsed Insulin Therapy in which a pre-treatment blood sugar level in the patient of at least 250-300 mg/dL, and the patient is treated with at least first and second cycles, each cycle comprising (1) pulsing a recombinant human insulin to the patient in concentrations of more than 10% to achieve a target intra-treatment blood sugar level (BSL) swing of more than 100 mg/dL, and (2) raising the blood sugar level to at least 250-300 mg/dL.Type: GrantFiled: December 14, 2010Date of Patent: March 12, 2013Inventors: Michael McCarthy, Marc Rose
-
Publication number: 20130058999Abstract: The invention is related to pharmaceutical compositions suitable for oral administration of insulin peptides, methods of making such and treatment with such.Type: ApplicationFiled: January 12, 2011Publication date: March 7, 2013Applicant: Novo Nordisk A/SInventor: Florian Anders Foeger
-
Patent number: 8389470Abstract: Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration. The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biological membrane in order to facilitate transport. In one embodiment, insulin is administered via the pulmonary delivery of microparticles comprising fumaryl diketopiperazine and insulin in its biologically active form. This method of delivering insulin results in a rapid increase in blood insulin concentration that is comparable to the increase resulting from intravenous delivery.Type: GrantFiled: January 5, 2011Date of Patent: March 5, 2013Assignee: MannKind CorporationInventors: Solomon S. Steiner, Rodney J. Woods, Joseph W. Sulner
-
Publication number: 20130052237Abstract: A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.Type: ApplicationFiled: August 29, 2012Publication date: February 28, 2013Applicant: INTARCIA THERAPEUTICS, INC.Inventors: Rom Ezer Eliaz, Yuanpeng Zhang, Catherine Manya Rohloff, Eric William Weeks, Gunjan Junnarkar
-
Patent number: 8383585Abstract: The invention provides compositions and methods for determining cardiodiabetes status in a subject. The invention also provides compositions and methods for treating a subject experiencing cardiodiabetes.Type: GrantFiled: July 17, 2009Date of Patent: February 26, 2013Assignee: IKFE Institut fur Klinische Forschung und Entwicklung GmbHInventors: Andreas Pfuetzner, Thomas Forst
-
Patent number: 8386187Abstract: Methods, reports and systems for generating insulin resistance indexes for assessing decreased insulin sensitivity and/or levels of insulin resistance using a plurality of different measured lipoprotein particle parameters.Type: GrantFiled: October 20, 2009Date of Patent: February 26, 2013Assignee: LipoScience, Inc.Inventor: James D. Otvos
-
Publication number: 20130034602Abstract: The invention relates to an enteric-coated capsule containing cationic nanoparticles for oral insulin delivery, in particular to a type of cationic nanoparticle including a polycationic and mucoadhesive polymer and a biodegradable polymer, wherein each of the nanoparticles has positive surface charge and enhanced permeability for paracellular insulin delivery; the enteric-coated capsule further includes a pH-sensitive polymer as the coating. The enteric-coated capsule containing cationic nanoparticles, when being orally administered to a subject, are configured to prevent the acidic degradation of the active substance such as insulin before being released from said cationic nanoparticles to a specific absorption site along the gastrointestinal tract.Type: ApplicationFiled: July 30, 2012Publication date: February 7, 2013Applicant: NANO AND ADVANCED MATERIALS INSTITUTE LIMITEDInventors: Yu QIAN, Li Juan ZHANG, Zhi Min WU, Li Ying ZHOU, Wei JIANG, Li LING, Qian LUO, Xin Dong GUO
-
Publication number: 20130034589Abstract: The present invention discloses the pH-sensitive nanoparticles composed of pH-sensitive polymer, hydrophobic material, internal stabilizer, external stabilizer content and insulin drug. The present invention also includes a method for preparation of pH-sensitive nanoparticles, in particular, a multiple emulsions solvent evaporation method. The pH-sensitive nanoparticles of the present invention show good pH-sensitive property with 100-300 nanometer particle size. Significant decrease in blood glucose level is observed in streptozotocin (STZ)-induced diabetic rats and the bioavailability of insulin is more than 10% after oral administration of the insulin-loaded pH-sensitive nanoparticles.Type: ApplicationFiled: July 30, 2012Publication date: February 7, 2013Applicant: NANO AND ADVANCED MATERIALS INSTITUTE LIMITEDInventors: Lijuan ZHANG, Li LING, Li Ying ZHOU, Zhi Min WU, Xin Dong GUO, Wei JIANG, Qian LUO, Yu QIAN
-
Patent number: 8361959Abstract: The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.Type: GrantFiled: September 30, 2009Date of Patent: January 29, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Andrew Stamford, Michael W. Miller, Duane Eugene DeMong, William J. Greenlee, Joseph A. Kozlowski, Brian J. Lavey, Michael K. C. Wong, Wensheng Yu, Xing Dai, De-Yi Yang, Guowei Zhou
-
Publication number: 20130012433Abstract: This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Ralf ROSSKAMP, Hertzel GERSTEIN
-
Publication number: 20120328688Abstract: A biocompatible film includes a single layer having a plurality of components, at least one of the plurality of components having a predetermined non-uniform distribution in the thickness direction of the single layer. The at least one of the plurality of components that has a non-uniform distribution in the thickness direction of the single layer may have a substantially uniform distribution in the longitudinal and lateral directions of the single layer. The biocompatible film can be made by depositing a fluid composition including a film forming material and at least one other component immiscible with the film forming material and having a density different than the film forming material into a single layer, and drying the single layer such that the at least one other component has a predetermined non-uniform distribution in the thickness direction of the single layer after drying.Type: ApplicationFiled: August 13, 2012Publication date: December 27, 2012Inventors: Richard C. Fuisz, Joseph M. Fuisz
-
Publication number: 20120328676Abstract: Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.Type: ApplicationFiled: August 22, 2012Publication date: December 27, 2012Inventors: Andrea Leone-Bay, Destardi Moye-Sherman, Bryan R. Wilson
-
Patent number: 8337817Abstract: Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising: a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties; and a physiologically active substance.Type: GrantFiled: December 25, 2007Date of Patent: December 25, 2012Assignee: Shin Nippon Biomedical Laboratories, Ltd.Inventors: Ryoichi Nagata, Shunji Haruta
-
Publication number: 20120316107Abstract: A fibrillation-resistant insulin analogue may be a single-chain insulin analogue or a physiologically acceptable salt thereof, containing an insulin A chain sequence or an analogue thereof and an insulin B chain sequence or an analogue thereof connected by a polypeptide of 4-10 amino acids. The fibrillation-resistant insulin analogue preferably displays less than 1 percent fibrillation with incubation at 37° C. for at least 21 days. A single-chain insulin analogue displays greater in vitro insulin receptor binding than normal insulin while displaying less than or equal binding to IGFR than normal insulin. The fibrillation-resistant insulin may be used to treat a patient using an implantable or external insulin pump, due to its greater fibrillation resistance.Type: ApplicationFiled: May 16, 2012Publication date: December 13, 2012Applicant: CASE WESTERN RESERVE UNIVERSITYInventor: Michael Weiss
-
Publication number: 20120316108Abstract: The present invention is directed to compositions and methods of preparation of phospholipid depots that are injectable through a fine needle.Type: ApplicationFiled: June 14, 2012Publication date: December 13, 2012Applicant: Latitude Pharmaceuticals Inc.Inventors: Andrew Xian Chen, Hailiang Chen
-
Patent number: 8329647Abstract: The invention provides compositions and methods for determining insulin resistance and/or pancreatic ?-cell dysfunction in a subject. The invention also provides compositions and methods for treating a subject according to the insulin resistance and/or pancreatic ?-cell dysfunction in the subject.Type: GrantFiled: July 17, 2009Date of Patent: December 11, 2012Assignee: IKFE Institut fur Klinische Forschung und Entwicklung GmbHInventors: Andreas Pfuetzner, Thomas Forst
-
Patent number: 8324157Abstract: Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.Type: GrantFiled: December 1, 2011Date of Patent: December 4, 2012Assignee: Novo Nordisk A/SInventors: Helle Birk Olsen, Svend Havelund, Ulla Ribel-Madsen, Jeppe Sturis, Helle Naver, Morten Schlein, Svend Ludvigsen
-
Patent number: 8324156Abstract: Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing ?-cell function, aiding in preventing ?-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration.Type: GrantFiled: August 24, 2009Date of Patent: December 4, 2012Assignee: Emisphere Technologies, Inc.Inventors: Ehud Arbit, Michael Goldberg, Shingal Majuru
-
Publication number: 20120301535Abstract: Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein differing species of peptides are bound to the nanoparticles and incorporated into various dosage forms.Type: ApplicationFiled: June 8, 2012Publication date: November 29, 2012Inventors: Phillip Williams, Thomas Rademacher, Alexander Mark Schobel, Eric Dadey
-
Publication number: 20120302498Abstract: It is described the preparation of Insulin like peptides, of chimeric Insulin like peptides and of their derivatives by the random combination of their chains A and their chains B and the pharmaceutical application of the obtained products.Type: ApplicationFiled: October 8, 2010Publication date: November 29, 2012Applicant: Chemical & Biopharmaceutical Laboratories of Patras SAInventors: Kleomenis Barlos, Konstantinos Barlos
-
Patent number: 8318154Abstract: Provided are combinations, compositions and kits containing an fast-acting insulin composition and a hyaluronan degrading enzyme composition formulated for parenteral administration. Such products can be used in methods of treating insulin-treatable diseases or conditions. Also provided are methods for administration of a fast-acting insulin and a hyaluronan degrading enzyme.Type: GrantFiled: April 28, 2009Date of Patent: November 27, 2012Assignee: Halozyme, Inc.Inventors: Gregory I. Frost, Igor Bilinsky, Daniel Vaughn, Barry Sugarman
-
Publication number: 20120289462Abstract: The present invention relates to an insulin preparation that contains a self-assembling peptide. More specifically, the present invention is an insulin preparation containing a self-assembling peptide of SEQ ID NO: 1.Type: ApplicationFiled: January 12, 2011Publication date: November 15, 2012Inventors: Nobuhito Shibata, Asako Nishimura
-
Patent number: 8309123Abstract: The present invention relates to pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes. The pharmaceutical compositions contain the at least one protein active ingredient, in free form, as well as, for liquids, a system that buffers them to a pH greater than 4 and less than or equal to 8 or, for solids, a system that exerts, when they are placed in a liquid medium, a buffer effect between a pH greater than 4 and a pH less than or equal to 8.Type: GrantFiled: December 19, 2008Date of Patent: November 13, 2012Inventors: Farid Bennis, Jean Jacques Serrano
-
Publication number: 20120277148Abstract: An insulin analogue comprises a B-chain polypeptide incorporating a chlorinated phenylalanine. The chlorinated phenylalanine may be located at position B24. The chlorinated phenylalanine may be para-monochloro-phenylalanine. The analogue may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analogue. The chlorinated insulin analogues retain significant activity. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. Chlorine substitution-based stabilization of insulin may reduce fibrillation and thereby enhance the treatment of diabetes mellitus in regions of the developing world lacking refrigeration.Type: ApplicationFiled: December 13, 2010Publication date: November 1, 2012Applicant: CASE WESTERN RESERVE UNIVERSITYInventor: Michael Weiss
-
Publication number: 20120277623Abstract: Methods and systems for delivering a probability that a subject has a medical condition are disclosed herein. The methods comprise calculating the probability of a medical condition using biomarker values and the rate of change of the biomarker values over time. In most embodiments, the methods comprise relations and calculations that require computer systems to execute the methods of the invention. Systems of the invention may include computer systems, as well as medical systems, such as biomarker assays and courses of medical action.Type: ApplicationFiled: March 26, 2012Publication date: November 1, 2012Applicant: Soar BioDynamics, Ltd.Inventor: Thomas Neville
-
Publication number: 20120269882Abstract: Methods and composition for the treatment of systemic inflammation, such as bacterial or viral sepsis, are described. Methods of treating systemic inflammation comprise delivery of insulin to the brain, for example by intracranial or intranasal administration. Insulin delivery systems and brain-targeted insulin compositions and polypeptides are also provided.Type: ApplicationFiled: May 19, 2010Publication date: October 25, 2012Applicant: MOUNT SINAI SCHOOL OF MEDICINE Office of Technology & Business DevelopmentInventor: Christoph Buettner
-
Publication number: 20120264681Abstract: The present disclosure provides a buffered ophthalmic composition for formulation of topically administrable suspensions useful for treating eye disorders by promoting wound healing, delivery of pharmaceutically active agents, and lubricating the eye. In particular the ophthalmic composition includes a buffer solution compatible with application to a mammalian eye, wherein the buffer provides increased mechanism of action of pharmaceutically active agents as well as therapeutic qualities. The ophthalmic composition exhibits dual therapeutic action to alleviate various eye disorders as it concomitantly treats corneal ulcerations and excessive inflammation which results from various eye injuries.Type: ApplicationFiled: November 8, 2011Publication date: October 18, 2012Applicant: HEALOR LTD.Inventors: Liora BRAIMAN-WIKSMAN, Yuval SAGIV, Ofra LEVY-HACHAM, Tamar TENNENBAUM
-
Publication number: 20120258176Abstract: The invention discloses particulate complexes composed of chitosan, poly-glutamic acid, and at least one bioactive agent, wherein equal moles of the positively charged chitosan and the negatively charged poly-glutamic acid substrate form an electrostatic network enabling improved loading the bioactive agent.Type: ApplicationFiled: May 7, 2012Publication date: October 11, 2012Inventors: Hsing-Wen Sung, Zi-Xian Liao, Shu-Fen Peng, Hosheng Tu